Melphalan Hydrochloride

DRUG8 trials

Sponsors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, University of Washington, Children's Oncology Group, City of Hope Medical Center, Roswell Park Cancer Institute

Conditions

Acute LeukemiaAcute Myeloid Leukemia in RemissionAdult Acute Lymphoblastic Leukemia in Complete RemissionBlasts 10 Percent or More of Bone Marrow Nucleated CellsChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaChronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Myelogenous Leukemia, BCR-ABL1 Positive in RemissionChronic Myelomonocytic Leukemia in Remission

Phase 1

Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).

CompletedNCT01688401

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsDiffuse Intrinsic Pontine Glioma (DIPG)

Start: 2013-03-08End: 2018-11-26Updated: 2019-03-28

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Active, not recruitingNCT03192397

Roswell Park Cancer InstituteAcute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission +10

Start: 2017-08-09End: 2027-05-21Updated: 2024-05-29

Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation

CompletedNCT03417284

M.D. Anderson Cancer CenterPlasma Cell Myeloma

Start: 2019-10-09End: 2024-07-18Updated: 2025-05-01

Phase 2

Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma

TerminatedNCT01293539

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsRetinoblastoma

Start: 2011-03-31End: 2016-08-31Updated: 2018-11-27

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

CompletedNCT02756572

University of WashingtonBlasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2, High Grade Malignant Neoplasm +6

Start: 2016-09-22End: 2020-07-01Updated: 2021-11-08

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

CompletedNCT03128359

City of Hope Medical CenterAcute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Myelogenous Leukemia, BCR-ABL1 Positive +12

Start: 2017-05-30End: 2021-09-15Updated: 2024-01-09

Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant

WithdrawnNCT03328936

Ohio State University Comprehensive Cancer CenterHematopoietic Cell Transplantation Recipient, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma

Start: 2018-09-01End: 2021-03-31Updated: 2020-02-21

Phase 3

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

RecruitingNCT03126916

Children's Oncology GroupGanglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma

Start: 2018-05-14End: 2030-09-30Target: 750Updated: 2026-02-27

Related Papers

Abstract A037 Changes in T-cell repertoire during high-risk neuroblastoma therapy: A report from the Children’s Oncology Group

Cancer Research2024-09-05

Inequitable Poverty Exposures: A Subspecialty Opportunity to Address Disparities

Hospital Pediatrics2024-01-195 citations

Feasibility and acceptability of social determinants of health data collection in the context of a Children’s Oncology Group trial.

Journal of Clinical Oncology2023-06-016 citations

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma

Nature Communications2023-05-0540 citations

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results

Nature Medicine2023-04-03111 citations

A Structural Racism Framework to Guide Health Equity Interventions in Pediatric Oncology

PEDIATRICS2022-04-0712 citations

A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N

Frontiers in Pediatrics2022-03-1026 citations

Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant

Blood Advances2021-06-2258 citations

A safety and feasibility trial of <sup>131</sup>I‐MIBG in newly diagnosed high‐risk neuroblastoma: A Children's Oncology Group study

Pediatric Blood & Cancer2021-05-2437 citations